Snapshot from Jun 09, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Gossamer_Bio faces securities fraud lawsuit
Regulatory class action lawsuit

Gossamer_Bio faces securities fraud lawsuit

Analysis based on 11 articles · First reported May 18, 2026 · Last updated May 28, 2026

Sentiment
-60
Attention
4
Articles
11
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Gossamer Bio is likely to negatively impact its stock price due to potential financial liabilities and damage to its reputation. Investors who purchased Gossamer Bio securities during the Class Period may experience losses, while the legal sector, specifically Bronstein, Gewirtz & Grossman, LLC, stands to gain from legal fees if the lawsuit is successful.

biotechnology legal services
Event Summary

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Gossamer Bio and its officers, alleging violations of federal securities laws. The lawsuit claims that Gossamer Bio made materially false and misleading statements between June 16, 2025, and February 20, 2026, concerning its Phase 3 PROSERA study. Specifically, the complaint alleges that Gossamer Bio concealed adverse facts about the study's design, including a failure to adequately control for placebo response at Latin American testing sites. As a result, Gossamer Bio's securities allegedly traded at artificially inflated prices, causing losses for investors. Bronstein, Gewirtz & Grossman, LLC is encouraging affected investors to join the lawsuit, with a deadline of June 1, 2026, to request lead plaintiff status.

Key Actions
100 Bronstein, Gewirtz & Grossman, LLC filed lawsuit Gossamer Bio
90 Gossamer Bio made false statements
Entities Involved
stock
Gossamer Bio
Gossamer Bio is the defendant in a class action lawsuit alleging securities fraud due to misleading statements about its Phase 3 PROSERA study, which could lead to significant financial damages and reputational harm.
Importance 100 Sentiment -70
priv
Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC is the law firm that filed the class action lawsuit against Gossamer Bio, representing investors seeking to recover damages.
Importance 80 Sentiment 50
per
Peretz Bronstein
Peretz Bronstein is the Founding Partner of Bronstein, Gewirtz & Grossman, LLC, actively involved in the class action lawsuit against Gossamer Bio.
Importance 60 Sentiment 40
per
Nathan Miller
Nathan Miller is a Client Relations Manager at Bronstein, Gewirtz & Grossman, LLC, assisting investors in joining the class action lawsuit.
Importance 40 Sentiment 30
index
Nasdaq-100
Nasdaq-100 is the stock exchange where Gossamer Bio's securities are traded, providing the platform for the alleged artificially inflated prices.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.